InvestorsHub Logo
Post# of 252278
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: DewDiligence post# 114429

Wednesday, 03/23/2011 1:47:51 PM

Wednesday, March 23, 2011 1:47:51 PM

Post# of 252278
GILD's elvitegravir met primary endpoint of noninferiority compared with Isentress in a phase III study 145:

http://finance.yahoo.com/news/Gilead-HIV-drug-meets-study-apf-4283405651.html?x=0&.v=1

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.